ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,099.96
1.02%
US Tech 100
17,244.00
1.57%
다우존스 지수
38,239.66
0.40%
Bitcoin
63,411.96
0.00%
Registration Strip Icon for charts 실시간 차트, 분석 도구 및 가격을 받으려면 등록하세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ
  6. Arvinas Inc (ARVN)

  7. Arvinas Inc (ARVN) 뉴스

ARVN Arvinas Inc

32.37
0.77 (2.44%)
27 4월(4) 2024 - 마감
15분 지연
기업명 주식 심볼 시장 주식 타입
Arvinas Inc ARVN 나스닥 보통주
  가격 변동 가격 변동 % 주식 가격 최근 거래 시간
Upgrade Icon
0.77 2.44% 32.37 06:44:30
개장가 저가 고가 종가 전일 종가
31.73 31.04 32.72 32.37 31.60
시세 정보 더보기 »

최근 뉴스

일자 시간 출처 제목
25/04/202405:30GLOBEArvinas Appoints Randy Teel, Ph.D., as Chief Business..
11/04/202420:00GLOBEArvinas Enters into a Transaction with Novartis, including a..
19/03/202405:40GLOBEArvinas Appoints Noah Berkowitz, M.D., Ph.D., as Chief..
04/03/202421:00GLOBEArvinas to Participate in Upcoming Investor Conferences
28/02/202408:35EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/02/202408:34EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/02/202408:33EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/02/202408:33EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/02/202406:46EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
27/02/202421:02EDGAR2Form 8-K - Current report
27/02/202421:00GLOBEArvinas Reports Fourth Quarter and Full Year 2023 Financial..
21/02/202406:06EDGAR2Form 8-K - Current report
21/02/202406:05GLOBEArvinas Announces Chief Financial Officer Transition
20/02/202421:00GLOBEArvinas Announces First-in-Human Dosing of ARV-102, an..
14/02/202422:00GLOBECarrick Therapeutics Announces First Patient Dosed in Phase..
14/02/202410:14EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
06/02/202420:45GLOBEArvinas and Pfizer’s Vepdegestrant (ARV-471) Receives FDA..
02/02/202406:30GLOBEArvinas to Present at 6th Annual Guggenheim Biotechnology..
17/01/202407:01GLOBEArvinas Appoints Jared Freedberg as General Counsel
17/01/202406:03EDGAR2Form S-8 - Securities to be offered to employees in employee..
09/01/202406:39EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/01/202421:45EDGAR2Form 8-K - Current report
08/12/202323:16EDGAR2Form S-3ASR - Automatic shelf registration statement of..
06/12/202321:01EDGAR2Form 8-K - Current report
06/12/202312:52GLOBEArvinas to Host Conference Call and Webcast to Discuss..
06/12/202303:33GLOBEArvinas and Pfizer Announce Interim Data from Phase 1b Trial..
29/11/202307:05GLOBEArvinas and Pfizer Announce Updated Vepdegestrant (ARV-471)..
27/11/202321:11EDGAR2Form 8-K - Current report
27/11/202321:00GLOBEArvinas Announces Oversubscribed $350 Million Private..
08/11/202307:24EDGAR2Form S-3ASR - Automatic shelf registration statement of..
08/11/202306:27EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/11/202321:03EDGAR2Form 8-K - Current report
07/11/202321:00GLOBEArvinas Reports Third Quarter 2023 Financial Results and..
02/11/202320:00GLOBEArvinas to Participate in Upcoming Investor Conferences
23/10/202321:30EDGAR2Form 8-K - Current report
22/10/202320:00GLOBEPotential of Arvinas’ PROTAC® AR Degraders Reinforced by..
18/10/202320:00GLOBEArvinas Gives Back to Local Greater New Haven Community in..
16/10/202307:07GLOBEArvinas Announces Upcoming Bavdegalutamide Poster..
16/10/202307:05GLOBEArvinas and Pfizer Announce Upcoming Vepdegestrant (ARV-471)..
01/09/202320:00GLOBEArvinas to Participate in Upcoming Investor Conferences
15/08/202306:27EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/08/202305:09EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/08/202320:03EDGAR2Form 8-K - Current report
08/08/202320:00GLOBEArvinas Reports Second Quarter 2023 Financial Results and..
01/08/202305:30GLOBEArvinas and Pfizer Awarded Innovation Passport Designation..
06/07/202322:00GLOBECarrick Therapeutics Announces Clinical Trial Collaboration..
16/06/202305:30GLOBEArvinas Announces Changes to its Board of Directors
08/06/202320:00GLOBEArvinas Announces Interim Data from the ARV-766 Phase 1/2..
05/06/202320:00GLOBEArvinas to Participate in Upcoming Investor Conferences
08/05/202320:00GLOBEArvinas and Pfizer Announce Upcoming Vepdegestrant (ARV-471)..

최근 히스토리

NASDAQ
ARVN
Arvinas
Delayed Upgrade Clock
ADVFN Logo

대한변국
회사 소개
사업
Popular
앱 받기

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2024 ADVFN PLC - 모든 권리 보유